CDRH Eyeing Drug Money, “True Dialogue” in User Fee Talks

article image

FDA device officials appear to be eyeing the big dollars tied to drug user fee programs with some envy, and other updates from the MDUFA V negotiations.

The device industry’s goal to keep FDA user fees close to current levels in the next round of the program (MDUFA V) is hitting a snag in early negotiation meetings with agency officials who are raising FDA drug user fees as a comparator.


This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to Market Pathways:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to Market Pathways
Sign up for All-Access

Join our global community with a subscription to both MedTech Strategist and Market Pathways for one low price.



We're here to help! Please contact us at: